已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial

医学 心房颤动 冲程(发动机) 随机对照试验 人口 不利影响 内科学 子群分析 物理疗法 急诊医学 儿科 置信区间 机械工程 环境卫生 工程类
作者
Märit Jensen,Anna Suling,Andreas Metzner,Renate B. Schnabel,Katrin Borof,Andreas Goette,Karl Georg Hæusler,Antonia Zapf,Karl Wegscheider,Larissa Fabritz,Hans‐Christoph Diener,Götz Thomalla,Paulus Kirchhof
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (1): 45-54 被引量:24
标识
DOI:10.1016/s1474-4422(22)00436-7
摘要

Patients with atrial fibrillation and a history of stroke are at high risk of recurrent stroke and cardiovascular complications. In the EAST-AFNET 4 trial we showed that a systematic strategy of early rhythm control was associated with a lower risk of cardiovascular outcomes than usual care in patients with atrial fibrillation diagnosed in the past 12 months. In this pre-specified subgroup analysis we aimed to assess whether a strategy of early rhythm control is safe and can prevent adverse cardiovascular outcomes compared with usual care in such patients.EAST-AFNET 4 was a randomised, open-label trial with blinded-outcome assessment done at 135 hospitals and secondary care practices in 11 European countries. Adults with early atrial fibrillation (ie, diagnosed ≤12 months before enrolment) were randomly assigned (1:1) to either early rhythm control or usual care, with stratification according to site and variable block lengths used for concealment. The first primary outcome was time to first occurrence of the composite of cardiovascular death, ischaemic or haemorrhagic stroke, or hospital admission with worsening of heart failure or acute coronary syndrome. The second primary outcome was the number of nights spent in hospital in 1 year. The primary safety outcome was the composite of any death, stroke, or serious adverse events related to rhythm-control therapy. Here we present the results of these outcomes in patients with a history of stroke. Analyses were done in the intention-to-treat population. EAST-AFNET 4 is registered with ClinicalTrials.gov (NCT01288352), EudraCT (2010-021258-20), and ISRCTN (ISRCTN04708680).Between July 28, 2011, and Dec 30, 2016, 2789 patients were randomly assigned in the EAST-AFNET 4 trial to either early rhythm control (n=1395) or usual care (n=1394). Of these patients, five had no information on history of stroke and were excluded from this subgroup analysis. 217 (8%) patients had a history of stroke, of whom 110 were assigned to early rhythm control and 107 to usual care. The median age of participants with a history of stroke was 72·0 years (IQR 66·0-76·0). 95 (44%) participants were female and 122 (56%) were male. During a median follow-up of 4·7 years (3·5-6·4) for patients with a history of stroke, a first primary outcome event occurred in 18 (16%) of 110 patients in the early rhythm-control group (3·7 per 100 person-years) and 33 (31%) of 107 in the usual care group (7·4 per 100 person-years; hazard ratio [HR] 0·52, 95% CI 0·29-0·93). The mean number of nights spent in hospital per year was 5·1 (SD 13·2) for patients with a history of stroke assigned to early rhythm control and 6·6 (10·1) for those assigned to usual care (incidence rate ratio 0·87, 95% CI 0·55-1·38). Among patients with a history of stroke, primary safety events occurred in 17 (15%) patients in the early rhythm-control group versus 30 (28%) in the usual care group.In this prespecified subgroup analysis in patients with recently diagnosed atrial fibrillation and a history of stroke, the effects of early rhythm control were consistent with the findings of the primary analysis. As the evidence from this subgroup analysis is considered supportive and exploratory, further research is needed to confirm the safety and efficacy of this approach in patients with a history of stroke.German Ministry of Education and Research, German Center for Cardiovascular Research (DZHK), Atrial Fibrillation Network (AFNET), European Heart Rhythm Association, St Jude Medical-Abbott, Sanofi, and the German Heart Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助张文懿采纳,获得10
3秒前
5秒前
8秒前
gaw2008发布了新的文献求助80
8秒前
cdercder应助肉桂采纳,获得10
8秒前
罗拉发布了新的文献求助10
9秒前
9秒前
zm完成签到,获得积分10
12秒前
pluto应助提拉米草采纳,获得10
13秒前
13秒前
XHMM发布了新的文献求助20
15秒前
16秒前
16秒前
品品完成签到,获得积分10
18秒前
隐形曼青应助woshidawan采纳,获得20
19秒前
21秒前
22秒前
科研通AI5应助风中的从凝采纳,获得10
22秒前
张文懿发布了新的文献求助10
22秒前
李健应助level采纳,获得100
23秒前
24秒前
高大寒梦发布了新的文献求助10
24秒前
25秒前
zhouyan160发布了新的文献求助10
26秒前
27秒前
风中太英关注了科研通微信公众号
28秒前
李健应助jsyfanature采纳,获得10
28秒前
wangdong应助研友_xnEOX8采纳,获得20
28秒前
蟹蟹发布了新的文献求助10
29秒前
30秒前
31秒前
31秒前
耿昊发布了新的文献求助10
32秒前
共享精神应助科研通管家采纳,获得10
33秒前
33秒前
33秒前
科研通AI5应助科研通管家采纳,获得10
33秒前
科研通AI5应助科研通管家采纳,获得10
33秒前
Akim应助科研通管家采纳,获得10
33秒前
大个应助科研通管家采纳,获得10
33秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
All the Birds of the World 4000
Production Logging: Theoretical and Interpretive Elements 3000
Musculoskeletal Pain - Market Insight, Epidemiology And Market Forecast - 2034 2000
Am Rande der Geschichte : mein Leben in China / Ruth Weiss 1500
CENTRAL BOOKS: A BRIEF HISTORY 1939 TO 1999 by Dave Cope 1000
Density Functional Theory: A Practical Introduction, 2nd Edition 840
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3749680
求助须知:如何正确求助?哪些是违规求助? 3292926
关于积分的说明 10078989
捐赠科研通 3008207
什么是DOI,文献DOI怎么找? 1652147
邀请新用户注册赠送积分活动 787169
科研通“疑难数据库(出版商)”最低求助积分说明 752013